Phaseline

Companies › Newave Pharmaceutical

Newave Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LP-118
selective treatment for hematological malignancies
–Phase 1Non Hodgkin Lymphoma; Acute Leukemia; Philadelphia Positive Acute Lymphoblastic LeukemiaDec 2026
LP-168
Small molecule inhibitor
–Phase 1CLL/SLL; Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06207123LP-118Phase 1Acute LeukemiaOncologyDec 2026
NCT04771572LP-118Phase 1Non Hodgkin LymphomaOncologyDec 2026
NCT04775745LP-168Phase 1CLL/SLLOncologyDec 2027
NCT06978088LP-168Phase 2Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaOncologyJun 2029
NCT07614022LP-118Phase 1Philadelphia Positive Acute Lymphoblastic LeukemiaOncologyMar 2030

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.